Einzeltreffer — DigiBib

Objectives: This study aimed to develop population norms for three preference-accompanied measures [EQ-5D-5L, Patient-Reported Outcomes Measurement Information System (PROMIS)-preference scoring system (PROPr) and Short-Form Six-Dimension (SF-6D)] in Hungary.

Methods: In November 2020, an online cross-sectional survey was conducted among a representative sample of the Hungarian adult general population (n = 1631). Respondents completed the Hungarian versions of the EQ-5D-5L, PROMIS-29+2 version 2.1 and 36-item Short Form Survey version 1 (SF-36v1). The association of utilities with sociodemographic and health-related characteristics of respondents was analysed using multivariate regressions.

Results: The proportion of respondents reporting problems ranged from 8 to 44% (self-care to pain/discomfort) on the EQ-5D-5L, 39-94% (physical function to sleep) on PROPr and 38-87% (role limitations to vitality) on the SF-6D. Problems related to physical function, self-care, usual activities/role limitations and pain increased with age, while mental health problems decreased in all three measures. In almost all corresponding domains, respondents indicated the fewest problems on the EQ-5D-5L and the most problems on the SF-6D. The mean EQ-5D-5L, PROPr and SF-6D utilities were 0.900, 0.535 and 0.755, respectively. Female gender (PROPr, SF-6D), a lower level of education (EQ-5D-5L, PROPr), being unemployed or a disability pensioner (EQ-5D-5L), being underweight or obese (SF-6D), lack of physical exercise (all) and polypharmacy (all) were associated with significantly lower utilities. PROPr yielded the lowest and EQ-5D-5L the highest mean utilities in 28 of 30 chronic health conditions.

Conclusions: This study presents the first set of Hungarian population norms for the EQ-5D-5L, PROPr and SF-6D. Our findings can serve as reference values in clinical trials and observational studies and contribute to the monitoring of population health and the assessment of disease burden in Hungary.

Titel:	Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.
Autor/in / Beteiligte Person:	Nikl, A ; Janssen, MF ; Jenei, B ; Brodszky, V ; Rencz, F
Link:	Full Text Finder (Volltext)
Zeitschrift:	PharmacoEconomics, Jg. 42 (2024-05-01), Heft 5, S. 583-603
Veröffentlichung:	Auckland : Adis, Springer International ; <i>Original Publication</i>: Auckland ; Philadelphia : Adis International, c1992-, 2024
Medientyp:	academicJournal
ISSN:	1179-2027 (electronic)
DOI:	10.1007/s40273-024-01360-4
Schlagwort:	Humans Hungary Male Female Middle Aged Adult Cross-Sectional Studies Aged Surveys and Questionnaires Young Adult Patient Reported Outcome Measures Adolescent Age Factors Quality of Life Health Status
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Pharmacoeconomics] 2024 May; Vol. 42 (5), pp. 583-603. <i>Date of Electronic Publication: </i>2024 Feb 28. MeSH Terms: Quality of Life* ; Health Status* ; Humans ; Hungary ; Male ; Female ; Middle Aged ; Adult ; Cross-Sectional Studies ; Aged ; Surveys and Questionnaires ; Young Adult ; Patient Reported Outcome Measures ; Adolescent ; Age Factors References: Arch Med Sci. 2017 Feb 1;13(1):191-200. (PMID: 28144271) ; Qual Life Res. 2018 Jul;27(7):1885-1891. (PMID: 29569016) ; Value Health. 2010 Aug;13(5):631-5. (PMID: 20412541) ; Pharmacoeconomics. 2018 Jun;36(6):645-661. (PMID: 29572719) ; Health Technol Assess. 2014 May;18(34):vii-viii, xiii-xxv, 1-188. (PMID: 24857402) ; Expert Rev Pharmacoecon Outcomes Res. 2023 Jun;23(5):449-468. (PMID: 36889006) ; Pharmacoeconomics. 2020 Feb;38(2):159-170. (PMID: 31761995) ; Health Qual Life Outcomes. 2020 Oct 7;18(1):333. (PMID: 33028345) ; J Patient Rep Outcomes. 2022 Jan 4;6(1):1. (PMID: 34982262) ; Qual Life Res. 2017 Dec;26(12):3409-3419. (PMID: 28875430) ; Qual Life Res. 2023 Nov;32(11):3147-3160. (PMID: 37347395) ; Med Care. 2020 Jun;58(6):557-565. (PMID: 32412942) ; Health Technol Assess. 2014 Feb;18(9):1-224. (PMID: 24524660) ; BMC Med Res Methodol. 2020 Oct 8;20(1):252. (PMID: 33032531) ; BMC Rheumatol. 2022 Mar 7;6(1):15. (PMID: 35249554) ; Qual Life Res. 2024 Jan;33(1):87-99. (PMID: 37707653) ; BMJ Open. 2019 Nov 21;9(11):e032859. (PMID: 31753898) ; Qual Life Res. 2016 Nov;25(11):2693-2710. (PMID: 27472992) ; Eur J Health Econ. 2023 Jun 28;:. (PMID: 37378690) ; Dermatitis. 2022 Nov-Dec 01;33(6S):S92-S103. (PMID: 35674639) ; Health Qual Life Outcomes. 2021 Apr 17;19(1):125. (PMID: 33865400) ; Eur J Health Econ. 2015 Apr;16(3):235-41. (PMID: 24504771) ; Med Decis Making. 2018 Aug;38(6):683-698. (PMID: 29944456) ; Qual Life Res. 2022 Jan;31(1):79-89. (PMID: 34181154) ; J Health Serv Res Policy. 1996 Jan;1(1):20-7. (PMID: 10180841) ; Pharmacoeconomics. 2022 Sep;40(9):863-882. (PMID: 35829931) ; Br Med Bull. 2010;96:5-21. (PMID: 21037243) ; Health Qual Life Outcomes. 2023 Feb 19;21(1):17. (PMID: 36803866) ; World Neurosurg. 2024 Jan;181:e55-e66. (PMID: 37385441) ; Eur J Health Econ. 2021 Jun;22(4):547-557. (PMID: 33761029) ; Value Health. 2020 Sep;23(9):1235-1245. (PMID: 32940242) ; Med Decis Making. 2017 Nov;37(8):882-893. (PMID: 28525725) ; Qual Life Res. 2019 Jan;28(1):141-152. (PMID: 30225788) ; Health Qual Life Outcomes. 2023 Jul 29;21(1):80. (PMID: 37507760) ; Value Health. 2019 May;22(5):537-544. (PMID: 31104731) ; Qual Life Res. 2011 Dec;20(10):1727-36. (PMID: 21479777) ; Qual Life Res. 2004 Sep;13(7):1217-23. (PMID: 15473500) ; Med Care. 2020 Jun;58(6):566-573. (PMID: 32221100) ; Qual Life Res. 2022 Oct;31(10):3049-3060. (PMID: 35471487) ; J Med Econ. 2023 Jan-Dec;26(1):584-593. (PMID: 36973235) ; J Clin Epidemiol. 2010 Nov;63(11):1179-94. (PMID: 20685078) ; Qual Life Res. 2017 Aug;26(8):2057-2066. (PMID: 28364183) ; Med Care. 2007 Dec;45(12):1162-70. (PMID: 18007166) ; Eur J Health Econ. 2023 Feb;24(1):139-152. (PMID: 35412162) ; Value Health. 2023 Jul;26(7):1045-1056. (PMID: 36804583) ; Qual Life Res. 2015 Oct;24(10):2559-64. (PMID: 25894065) ; J Prev Med Public Health. 2017 Nov;50(6):361-368. (PMID: 29207449) ; BMC Geriatr. 2017 Oct 10;17(1):230. (PMID: 29017448) ; Med Decis Making. 2015 Apr;35(3):276-91. (PMID: 25159172) ; Pain. 2008 Sep 30;139(1):146-157. (PMID: 18455312) ; Qual Life Res. 2012 Aug;21(6):1013-20. (PMID: 21909804) ; J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2584-2592. (PMID: 32618022) ; Patient. 2023 May;16(3):201-221. (PMID: 36786931) ; Br J Dermatol. 2019 Apr;180(4):802-809. (PMID: 29897626) ; Med Decis Making. 2019 Jul;39(5):605-616. (PMID: 31257997) ; Med Care. 1992 Jun;30(6):473-83. (PMID: 1593914) ; Eur J Health Econ. 2020 Nov;21(8):1245-1257. (PMID: 32514643) ; Qual Life Res. 2005 Mar;14(2):493-500. (PMID: 15892438) ; Eur J Health Econ. 2018 Jun;19(5):675-686. (PMID: 28631248) ; J Med Econ. 2022 Jan-Dec;25(1):829-839. (PMID: 35674412) ; Qual Life Res. 2021 Mar;30(3):647-673. (PMID: 33284428) ; Qual Life Res. 2009 Mar;18(2):267-72. (PMID: 19105049) ; J Health Econ. 2002 Mar;21(2):271-92. (PMID: 11939242) ; Qual Life Res. 2023 Aug;32(8):2179-2194. (PMID: 36792819) ; Appl Health Econ Health Policy. 2022 Jul;20(4):573-585. (PMID: 35132573) ; Clin J Am Soc Nephrol. 2021 Sep;16(9):1328-1336. (PMID: 34272256) ; Eur J Health Econ. 2020 Nov;21(8):1169-1178. (PMID: 32813084) ; Curr Med Res Opin. 2009 Apr;25(4):929-42. (PMID: 19257798) ; Aust N Z J Public Health. 2013 Feb;37(1):17-23. (PMID: 23379801) ; Med Care. 2007 May;45(5 Suppl 1):S22-31. (PMID: 17443115) ; Health Policy. 1990 Dec;16(3):199-208. (PMID: 10109801) ; Orv Hetil. 2003 Aug 24;144(34):1667-74. (PMID: 14528840) ; Qual Life Res. 2016 Mar;25(3):707-19. (PMID: 26303761) ; Qual Life Res. 2018 Sep;27(9):2349-2359. (PMID: 29797176) ; Qual Life Res. 2021 May;30(5):1477-1490. (PMID: 33534032) ; Pharmacoeconomics. 2022 Mar;40(3):297-307. (PMID: 34786591) ; Value Health Reg Issues. 2020 Sep;22:61-67. (PMID: 32798836) ; Eur J Health Econ. 2015 Dec;16(9):1019-26. (PMID: 25519850) ; Health Econ. 2012 Dec;21(12):1508-12. (PMID: 22250070) ; Pharmacoeconomics. 2017 Dec;35(Suppl 1):21-31. (PMID: 29052157) ; Health Qual Life Outcomes. 2021 Sep 22;19(1):221. (PMID: 34551778) ; Value Health. 2022 Dec;25(12):2003-2016. (PMID: 35973925) Grant Information: MTA-PPD 462025 Hungarian Academy of Sciences; ÚNKP-23-3-II-SE-17 New National Excellence Program of the Ministry for Culture and Innovation; ÚNKP-23-5-CORVINUS-5 New National Excellence Program of the Ministry for Culture and Innovation; BO/00304/21 János Bolyai Research Scholarship of the Hungarian Academy of Sciences Entry Date(s): Date Created: 20240228 Date Completed: 20240423 Latest Revision: 20240426 Update Code: 20240426 PubMed Central ID: PMC11039522

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.